Johnson & Johnson

JNJ.US ยท Healthcare ยท Drug Manufacturers - General ยท USD ยท Fundamentals
Asset-light

Physical assets are 19.4% of total assets, a light footprint. Capex is 0.64x depreciation while free cash flow yield is positive, which can mean an aging base that is still throwing off cash. ROIC is 19.3%, above an 8% cost-of-capital hurdle.

Fixed-asset turnover is 3.85x. Compare it with other names in the same basket.

Physical asset ratio
19.4%
Net PP&E plus inventory, divided by total assets. Above 50% is a heavy footprint.
Fixed asset turnover
3.85x
Revenue per dollar of the physical asset base.
Capex / D&A
0.64x
Above 1.0x means the physical base is being replaced or expanded.
Tangible book / share
-$7.26
Assets minus goodwill, intangibles, and liabilities, per share.
Price / tangible book
โ€”
Price $253.37.
Fixed-charge coverage
3.83x
EBITDA minus capex, divided by interest plus short-term debt.
FCF yield
3.2%
Latest free cash flow divided by current market cap ($611.90B).
ROIC
19.3%
After-tax operating income over equity plus debt minus cash. Operating income / net PP&E is 1.05x.

Footprint and return

Turnover and reinvestment

Year Physical FAT Capex/D&A TBV/sh Coverage FCF ROIC EBIT/PP&E
2018 16.8% 4.79x 0.53x -$6.71 5.86x $18.53B 25.5% 1.24x
2019 16.9% 4.65x 0.50x -$8.13 13.92x $19.92B 27.0% 1.19x
2020 16.1% 4.40x 0.46x -$9.93 7.27x $20.19B 24.0% 1.05x
2021 16.1% 4.15x 0.49x -$2.85 5.85x $19.76B 25.5% 1.10x
2022 16.0% 4.04x 0.58x $0.85 1.73x $17.19B 18.9% 1.06x
2023 19.1% 4.07x 0.61x -$0.77 5.28x $18.25B 25.7% 1.05x
2024 18.9% 4.11x 0.60x -$4.25 3.02x $19.84B 22.3% 1.02x
2025 19.4% 3.85x 0.64x -$7.26 3.83x $19.70B 19.3% 1.05x
  • Principal due is short-term debt, the amount reported as due within a year.
Latest year inputs (2025)
Net PP&E: $24.47B
Inventory: $14.19B
Total assets: $199.21B
Goodwill: $48.77B
Intangibles: $50.40B
Liabilities: $117.67B
Tangible book: -$17.63B
Shares: 2,429,400,000
Revenue: $94.19B
Capex: $4.83B
D&A: $7.50B
EBITDA: $41.06B
Interest: $971.00M
Short-term debt: $8.50B
Free cash flow: $19.70B
Operating income: $25.60B
Invested capital: $109.38B
Tax rate: 17.7%